Y2020

UK Antibiotic Subscription Pilot: Post-webinar FAQ document

Dear All, Kevin Outterson and I recently shared our analysis of the NICE/NHS England pilot of an antibiotic procurement subscription model (link to that newsletter). The NICE/NHS team have now released a post-webinar FAQ document. Here is the link to the document … and I’ve also added the link to the initial webpage (cited just above) discussing

Read More »

WHO consultancy: Create online e-learning on antimicrobial stewardship

Dear All, WHO today published a Request for Proposals (RFP) for a consultant to develop an online e-learning course on antimicrobial stewardship! There is a mention of the request on the WHO AMR homepage (link) which in turn takes you to the extended details in this Terms of Reference document (link). In brief, the project

Read More »

UK Antibiotic Subscription Pilot implies Pull Incentive of up to $4b across the G20

Note that there is a follow-up newsletter that covers a post-webinar FAQ. After reading this newsletter as introduction, please go here for the follow-up newsletter. Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Prior newsletters have covered the antibiotic evaluation procurement pilot being run by NICE and NHS England (go here for the

Read More »

Let’s help Alan Carr do a COVID-19 point insight survey

Dear All, I promise that the next email will be all about the 25 Mar 2020 NHS England webinar on their antibiotic evaluation and procurement pilot (you’re going to love it … NICE and NHS England are doing great stuff … go here if you want to see a prior newsletter on this topic), BUT

Read More »

Send a note to your congressman/woman today!

Dear All, If you are a US citizen, you have an opportunity right now (as in today/tomorrow) to push for the inclusion of the DISARM Act in the COVID-19 bill(s) currently being circulated in Congress. As a reminder, DISARM is the legislation that would reimburse QIDP antimicrobials in the hospital setting outside of the DRG

Read More »

Tetraphase sold for $14m … and $600m goes up in smoke!

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter): Wonkish and long note alert … top-up your coffee and settle in… We learned about a week ago that Tetraphase, despite having brought an antibacterial (eravacycline) to approval, has been sold for stock worth $14.4m (plus a potential $12.5m more if aggressive sales targets are achieved).

Read More »

Pull incentives for antibiotics: How much and why? — A literature survey

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), The recent discussions of the NICE/NHS England pilot subscription model (detailed newsletter plus follow-up FAQ newsletter) and a new paper by Chantal Morel and colleagues on the idea of an Antibiotic Susceptibility Bonus (ASB, link) bring to the fore the question of how to value any given

Read More »

Beyond the AMR Action Fund: PBS NewsHour and Things for us all to do!

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), While we’re all thrilled with the announcement of the AMR Action Fund (newsletter), we’ve also had in parallel a demonstration of why the fund alone is insufficient to solve the antibiotic innovation crisis (newsletter on withdrawal of plazomicin’s marketing application in Europe). Thus, it’s

Read More »
Scroll to Top